title: Successful treatment with third stem cell transplant from an allogeneic donor for a patient with relapsed diffuse large B-cell lymphoma.
abstract: High-dose chemotherapy with autologous stem cell transplant is commonly used for diffuse large B-cell lymphoma that recurs after successful salvage chemotherapy. However, in patients in whom the disease recurs again, the prognosis is poor. A 40-year-old woman who underwent allogeneic stem cell transplant 4 years after autologous stem cell transplant developed recurrent diffuse large B-cell lymphoma 3 years after the initial autologous stem cell transplant. She then underwent reduced-intensity hematopoietic stem cell transplant from a human leukocyte antigen-matched, unrelated donor who was not the previous autologous stem cell transplant donor. She achieved a long survival (328 days after the reduced-intensity hematopoietic stem cell transplant and 1844 days after the first allogeneic transplant). A second allogenic transplant may provide survival benefits in a proportion of patients with malignant lymphoma recurring after allogeneic transplant, although careful consideration is required because of the high risk of treatment-related mortality with second allogenic transplant.
authors: Department of Medical Oncology, Kanagawa Cancer Center, Asahi-ku, Yokohama, Japan. takasakih@kcch.jp
authors: Hirotaka
authors: H
authors: Takasaki
authors: Yoshimi
authors: Y
authors: Ishii
authors: Wataru
authors: W
authors: Yamamoto
authors: Hitoshi
authors: H
authors: Tsuchihashi
authors: Shigeki
authors: S
authors: Motomura
authors: Naoto
authors: N
authors: Tomita
authors: Yoshiaki
authors: Y
authors: Ishigatsubo
authors: Rika
authors: R
authors: Sakai
mesh_terms: D000328:Adult; D002908:Chronic Disease; D005260:Female; D006084:Graft Rejection / Q000276:immunology / Q000628:therapy*; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006650:Histocompatibility Testing; D006801:Humans; D007519:Isoantigens / Q000276:immunology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000628:therapy*; D012008:Recurrence; D019233:Retreatment; D014019:Tissue Donors; D014184:Transplantation, Homologous
chemical_list: D007519:Isoantigens